Nicotinamide mononucleotide vs nicotinamide riboside — what the human research actually shows, who should take which, and the honest answer on bioavailability.
Both NMN and NR raise NAD+ levels in humans. NR has more published human clinical trials and a longer safety record. NMN has robust animal data and early human evidence suggesting comparable or slightly superior bioavailability at equivalent doses. NMN costs more per gram. The honest answer: either works — consistency beats brand loyalty. Choose NR if price and human evidence matter most; choose NMN if you're following the Sinclair protocol or want sublingual dosing options.
| Factor | NMN (Nicotinamide Mononucleotide) | NR (Nicotinamide Riboside) |
|---|---|---|
| Full molecule name | +-Nicotinamide mononucleotide | Nicotinamide riboside chloride |
| Molecular weight | 334.2 Da (larger) | 255.3 Da (smaller) |
| Bioavailability | Debated — high sublingual | Well-established oral |
| NAD+ increase (human data) | 40–90% blood NAD+ rise | 40–140% blood NAD+ rise |
| Standard dose | 250–1000 mg/day | 250–500 mg/day |
| Human RCTs published | ~5–7 (growing) | 15+ (better studied) |
| Cost per month | $40–$80 (500mg/day) | $25–$55 (300mg/day) |
| Stability | Degrades in heat/light | Relatively stable |
| FDA status (US) | Dietary supplement (GRAS under review) | Dietary supplement (NDI filed) |
| Key researcher | David Sinclair (Harvard), Imai Lab (Wash U) | Charles Brenner (ChromaDex), Elysium Health |
| Notable brand | ProHealth, Renue By Science, DoNotAge | Tru Niagen (ChromaDex), Basis (Elysium) |
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell. It sits at the center of energy metabolism — it is the electron shuttle in the mitochondrial electron transport chain — and it is also the substrate for a set of proteins with direct relevance to aging.
Sirtuins (SIRT1–SIRT7): NAD+-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammation. Sirtuins consume NAD+ as part of their catalytic cycle — they need it in abundance to function. Caloric restriction extends lifespan in animals partly by raising NAD+ and activating sirtuins.
PARP enzymes: Poly(ADP-ribose) polymerases repair DNA strand breaks. They consume enormous quantities of NAD+ when DNA damage is high — which happens more frequently as we age due to accumulated oxidative stress.
CD38: An NAD+ glycohydrolase expressed on immune cells. CD38 activity increases substantially with age, consuming NAD+ — and CD38 knockout mice maintain youthful NAD+ levels significantly longer than wild-type animals. This "CD38 problem" is one reason supplementation becomes relevant: you're trying to keep pace with increasing consumption.
Zhu et al. (2015) and subsequent metabolomics studies show NAD+ declines in skeletal muscle, liver, and brain with age. The decline correlates with mitochondrial dysfunction and increased inflammatory signaling (SASP from senescent cells). Whether restoring NAD+ reverses these outcomes in humans remains an open question — but the biology is sound.
Nicotinamide riboside was first identified as a NAD+ precursor by Charles Brenner at the University of Iowa in 2004. It enters cells via nucleoside transporters and is phosphorylated to NMN, then to NAD+. It does not require the CD73 enzyme that NMN theoretically does for cell entry — though that debate has largely resolved (more below).
ChromaDex commercialized NR as Tru Niagen and funded multiple independent human trials. The evidence base for NR is the most robust of any NAD+ precursor:
First human trial of NR. Single-dose NR (100–1000mg) increased blood NAD+ metabolites in a dose-dependent manner. Chronic 250mg/day supplementation raised NAD+ in peripheral blood mononuclear cells significantly. No adverse effects reported. N=12 (small but landmark).
N=24 overweight adults. 1000mg/day NR for 6 weeks. NAD+ metabolites increased significantly in skeletal muscle (+127%). Aortic stiffness reduced in a subgroup. No significant effects on blood pressure, body weight, or insulin sensitivity. Demonstrates tissue-specific NAD+ elevation beyond blood.
Elysium Health's Basis product (250mg NR + 50mg pterostilbene) showed ~40% blood NAD+ elevation in a randomized, double-blind, placebo-controlled trial (N=120). 500mg NR component produced ~90% increase. No serious adverse events over 8 weeks. This is the largest RCT of an NR product to date.
300–500mg/day is the typical range for NAD+ elevation. Tru Niagen doses at 300mg per capsule. Higher doses (1000mg) have been studied without toxicity. Morning dosing is common but timing effects have not been definitively established. Take with or without food — absorption appears similar.
NMN is one step further down the NAD+ biosynthesis pathway than NR — it is converted directly to NAD+ by the enzyme NMNAT, without an intermediate step. This is why some researchers hypothesize NMN may be more efficient. NMN is also the precursor that David Sinclair has made famous through his research and self-experimentation.
David Sinclair's lab at Harvard published landmark mouse studies showing NMN reverses physiological aging phenotypes: NMN-supplemented aging mice showed improved muscle function, energy metabolism, eye function, and bone density. Shin-ichiro Imai's lab at Washington University in St. Louis showed NMN prevented age-related declines in female mice's muscle and energy metabolism and extended lifespan in mice fed a high-fat diet.
Critically: these are mouse studies. Mice convert NAD+ precursors more efficiently and have a very different NAD+ metabolism timeline. The extrapolation to humans requires human data — which is now starting to arrive.
A 2019 paper argued NMN is too large to enter cells directly and must first be converted to NR outside the cell — which would make it essentially equivalent to NR. This view has been challenged by the discovery of a specific NMN transporter (Slc12a8) in mouse intestinal cells that imports NMN directly. Whether this transporter is functionally significant in humans, and whether it matters for systemic NAD+ elevation, is still being studied.
First human safety trial of NMN. N=10 healthy men, single oral doses of 100, 250, and 500mg. NMN was safely metabolized and increased blood NAD+ and NAM metabolites in a dose-dependent manner. No serious adverse effects. NMN was detectable in blood within minutes, suggesting it survives gastric transit intact — countering the "NMN must convert to NR first" argument.
N=25 postmenopausal women with prediabetes. 250mg/day NMN for 10 weeks. Significant increase in skeletal muscle NAD+ metabolites. Significant improvement in insulin sensitivity of skeletal muscle specifically. No changes in body composition, blood pressure, or other metabolic markers. First proof of tissue-level functional effect in humans.
Some brands market sublingual (under-the-tongue) NMN powder or lozenges, arguing it bypasses first-pass hepatic metabolism and delivers NMN directly to circulation. There is no published human pharmacokinetic comparison of sublingual vs. oral NMN. The Irie 2020 data suggests oral NMN does reach blood intact. Sublingual absorption may offer faster onset but whether it meaningfully increases total NAD+ elevation is unconfirmed.
As of 2024, no large randomized controlled trial has directly compared NMN vs NR in the same human subjects. Most comparison claims are extrapolated from separate trial populations with different doses, populations, and measurement methods. That caveat matters.
Across available trials: NR at 300–500mg raises blood NAD+ ~40–90%. NMN at 250–500mg raises blood NAD+ ~40–70% in the studies measuring it. NMN at 900–1000mg (Pencina et al., 2023) raised NAD+ ~38% vs placebo. These ranges overlap substantially, suggesting comparable efficacy at equivalent doses. No study has shown one is meaningfully superior in humans.
N=30 healthy men aged 45–60. 900mg/day NMN vs placebo for 8 weeks. Significant increases in NAD+ and NAAD in blood. Trends toward improved walking speed and muscle strength. No significant changes in body composition. This is one of the larger NMN RCTs and shows functional signal in aging men, though effect sizes were modest.
No human RCT has demonstrated that NMN or NR extends lifespan, reduces biological age (by epigenetic clock), or prevents specific age-related diseases. What has been shown: both raise NAD+. Some trials show secondary metabolic benefits (insulin sensitivity, muscle function). These are promising but insufficient to make longevity claims. Researchers including Sinclair himself acknowledge this is a bet on mechanism, not proven outcome.
NR: 300–500mg/day. Most trials used 300mg (Tru Niagen dose) to 500mg. No strong evidence that more than 500mg adds proportional benefit, though 1000mg has been studied safely.
NMN: 250–500mg/day for most people. Sinclair reportedly takes 1g/day — this exceeds what most human trials have used and is self-experimentation at a dose without long-term safety data. Start at 250–500mg.
Morning is common practice. Some researchers suggest NAD+ may interact with circadian rhythms — SIRT1 is involved in clock regulation — so morning dosing may be preferable. No clinical trial has demonstrated timing-dependent effects in humans.
Resveratrol: Often paired with NMN because Sinclair's lab showed resveratrol activates SIRT1 and NMN provides the NAD+ substrate sirtuins need. The synergy is mechanistically compelling. Human evidence for the combination is limited. Resveratrol has poor oral bioavailability; some take it with fat or olive oil to improve absorption.
TMG (trimethylglycine / betaine): NMN metabolism may consume methyl groups, potentially depleting SAM (the universal methyl donor) over time. Some practitioners add 500–1g TMG as a precautionary methyl donor. This is theoretical — no human trial has confirmed TMG is necessary or beneficial alongside NMN/NR.
Browse nicotinamide mononucleotide supplements on Amazon. Filter for third-party tested, stabilized formulas.
Nicotinamide riboside — including Tru Niagen (ChromaDex), the most clinically validated NR brand.
Neither has been proven to extend human lifespan. NR has more published human clinical trials showing NAD+ elevation and secondary metabolic effects. NMN has fewer human trials but robust animal data and a growing human evidence base. Both raise NAD+ comparably in the trials conducted so far. The evidence does not support claiming one is definitively better — consistency of use matters more than which precursor you choose.
David Sinclair has publicly stated he takes 1g of NMN daily, along with resveratrol, metformin (prescription), and several other supplements. He is a co-founder of companies with commercial interests in the longevity space. This is self-experimentation — not a clinical endorsement. His own Harvard lab's foundational longevity work primarily studied NAD+ precursors in mice. He is transparent that human outcomes at these doses are unproven.
Most people report no acute subjective effects — these are not stimulants. NAD+ blood levels begin rising within days of supplementation. If functional outcomes occur — improved energy, sleep quality, or cognitive clarity — they are typically reported after 4–8 weeks of consistent daily use. Individual responses vary considerably. The primary benefit being targeted (slowed aging biology) is not subjectively detectable and may require years of consistent use to manifest as measurable differences in biomarkers like epigenetic age.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.